What SEC filings does Anika Therapeutics, Inc. submit to the SEC?

Anika Therapeutics, Inc. (ANIK) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about ANIK?

A Form 4 for ANIK discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from Anika Therapeutics, Inc.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for ANIK?

The 10-K is Anika Therapeutics, Inc.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all ANIK SEC filings directly on EDGAR?

You can view all historical Anika Therapeutics, Inc. filings on the SEC EDGAR company page for ANIK. Each filing card on this page links directly to the original SEC document.

How often does Anika Therapeutics, Inc. file with the SEC?

Anika Therapeutics, Inc. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling ANIK shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

ANIK SEC Filing News — Anika Therapeutics, Inc.

Latest SEC filings for Anika Therapeutics, Inc. (ANIK) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-08-07.

Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-opioid, single-injection OA pain management product; regenerative solutions, including an HA-based scaf…

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic Market Cap: $272.8M

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for ANIK currently lean bullish. Of the 20 displayed SEC filing records, 3 carry bullish classifications versus 0 bearish classifications. These labels summarize filing attributes; they are not recommendations, probabilities, or evidence of future price direction. There were 13 insider transactions (Form 4) in this period.

ANIK Filing Activity Snapshot 2026-03-17 — 2026-08-07

Insider Transactions (Form 4)

3 buys vs 0 sells

Net insider buying in this period — more purchases than sales reported.

Largest Form 144 Filing

$355.3K

Jellison William R · 2026-08-07

16,864 shares · Form 144

Form 144 Notices

Proposed insider sale filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.

Insider Transactions 13 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 13 filings in this group are Form 4s for Anika Therapeutics, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 13 insider filings shown, the breakdown is 9 compensation award, 3 open-market purchase and 1 option exercise. 3 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Compensation award ×9: Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Open-market purchase ×3: The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.
Option exercise ×1: The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Form 4 Open-market purchase Insider Buying 2026-08-05

ANIK insider Fischetti Gary P (Director) bought 2,000 shares (~$41.1K)

Fischetti Gary P, listed as Director at Anika Therapeutics, Inc., reported an open-market purchase of 2,000 ANIK shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	1,000	$20.75	$20.7K
`P`	Open-market purchase	1,000	$20.32	$20.3K

Filing: Form 4 (Insider Transaction) Insider: Fischetti Gary P (Director) Shares: 2,000 Est. Value: $41.1K

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-23

ANIK insider Form 4 filed for equity award, exercise, or tax withholding

Fischetti Gary P (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	10,402	—	—

Filing: Form 4 (Insider Transaction) Insider: Fischetti Gary P (Director) Shares: 10,402

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-23

ANIK insider Form 4 filed for equity award, exercise, or tax withholding

HENNEMAN JOHN B III (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	10,402	—	—

Filing: Form 4 (Insider Transaction) Insider: HENNEMAN JOHN B III (Director) Shares: 10,402

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-23

ANIK insider Form 4 filed for equity award, exercise, or tax withholding

Richard Stephen (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	10,402	—	—

Filing: Form 4 (Insider Transaction) Insider: Richard Stephen (Director) Shares: 10,402

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-23

ANIK insider Form 4 filed for equity award, exercise, or tax withholding

Capper Joseph H (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	10,402	—	—

Filing: Form 4 (Insider Transaction) Insider: Capper Joseph H (Director) Shares: 10,402

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-23

ANIK insider Form 4 filed for equity award, exercise, or tax withholding

CONLEY SHERYL L (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	10,402	—	—

Filing: Form 4 (Insider Transaction) Insider: CONLEY SHERYL L (Director) Shares: 10,402

View on SEC EDGAR → Open Filing Document →

Form 4 Option exercise Tax / Compensation Filing 2026-06-05

ANIK insider Form 4 filed for equity award, exercise, or tax withholding

Griffin Stephen D. (Director, President and CEO) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	12,840	—	—
`F`	Tax withholding on vested shares	3,769	$14.41	$54.3K
`M`	Option exercise derivative · Restricted Stock Unit	12,840	—	—

Filing: Form 4 (Insider Transaction) Insider: Griffin Stephen D. (Director, President and CEO) Shares: 16,609

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-05-04

ANIK insider HENNEMAN JOHN B III (Director) bought 5,000 shares (~$73.3K)

HENNEMAN JOHN B III, listed as Director at Anika Therapeutics, Inc., reported an open-market purchase of 5,000 ANIK shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	5,000	$14.66	$73.3K

Filing: Form 4 (Insider Transaction) Insider: HENNEMAN JOHN B III (Director) Shares: 5,000 Est. Value: $73.3K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-04-30

ANIK insider Griffin Stephen D. (Director, President and CEO) bought 12,200 shares (~$149.9K)

Griffin Stephen D., listed as Director, President and CEO at Anika Therapeutics, Inc., reported an open-market purchase of 12,200 ANIK shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	12,200	$12.29	$149.9K

Filing: Form 4 (Insider Transaction) Insider: Griffin Stephen D. (Director, President and CEO) Shares: 12,200 Est. Value: $149.9K

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-03-23

ANIK insider Form 4 filed for equity award, exercise, or tax withholding

McLeod Ian (SVP, CAO & Treasurer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Restricted Stock Unit	13,097	—	—
`A`	Compensation award derivative · Restricted Stock Unit	11,194	—	—
`A`	Compensation award derivative · Premium Priced Stock Appreciation Rights	17,663	—	—

Filing: Form 4 (Insider Transaction) Insider: McLeod Ian (SVP, CAO & Treasurer)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-03-17

ANIK insider Form 4 filed for equity award, exercise, or tax withholding

Colleran David (EVP, General Counsel, Corp Sec) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	9,388	—	—
`A`	Compensation award	4,694	—	—
`F`	Tax withholding on vested shares	4,168	$14.20	$59.2K
`M`	Option exercise	6,449	—	—
`F`	Tax withholding on vested shares	1,893	$14.20	$26.9K
`M`	Option exercise derivative · Restricted Stock Unit	9,388	—	—
`M`	Option exercise derivative · Restricted Stock Unit	6,449	—	—

Filing: Form 4 (Insider Transaction) Insider: Colleran David (EVP, General Counsel, Corp Sec) Shares: 26,592

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-03-17

ANIK insider Form 4 filed for equity award, exercise, or tax withholding

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	12,824	—	—
`A`	Compensation award	6,412	—	—
`F`	Tax withholding on vested shares	5,944	$14.20	$84.4K
`M`	Option exercise derivative · Restricted Stock Unit	12,824	—	—

Filing: Form 4 (Insider Transaction) Insider: Griffin Stephen D. (Director, President and CEO) Shares: 25,180

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-03-17

ANIK insider Form 4 filed for equity award, exercise, or tax withholding

Blanchard Cheryl R (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	24,519	—	—
`A`	Compensation award	24,520	—	—
`F`	Tax withholding on vested shares	14,728	$14.20	$209.1K
`M`	Option exercise	25,131	—	—
`F`	Tax withholding on vested shares	12,104	$14.20	$171.9K
`M`	Option exercise derivative · Restricted Stock Unit	24,519	—	—
`M`	Option exercise derivative · Restricted Stock Unit	25,131	—	—

Filing: Form 4 (Insider Transaction) Insider: Blanchard Cheryl R (Director) Shares: 101,002

View on SEC EDGAR → Open Filing Document →

Proposed Insider Sales 1 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Anika Therapeutics, Inc. has 1 such notice in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-08-07

ANIK Form 144 filed for proposed insider sale by Jellison William R (16,864 shares) ~$355.3K

Jellison William R filed a Form 144 with the SEC indicating intent to sell ANIK (Anika Therapeutics, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Jellison William R Shares: 16,864 Est. Value: $355.3K

View on SEC EDGAR → Open Filing Document →

Material Events 4 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 4 in this period for Anika Therapeutics, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-07-29

ANIK filed 8-K — material company event

Anika Therapeutics, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-07-14

ANIK filed 8-K — material company event

Anika Therapeutics, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-06-23

ANIK filed 8-K — material company event

Anika Therapeutics, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-04-29

ANIK filed 8-K — material company event

Anika Therapeutics, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Periodic Reports 2 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 2 quarterly reports (10-Q) for Anika Therapeutics, Inc.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-07-29

ANIK filed Quarterly Report (10-Q)

Anika Therapeutics, Inc. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)

View on SEC EDGAR → Open Filing Document →

Form 10-Q Quarterly Report 2026-04-30

ANIK filed Quarterly Report (10-Q)

Anika Therapeutics, Inc. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)

View on SEC EDGAR → Open Filing Document →

How we classify Anika Therapeutics, Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on ANIK. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — ANIK SEC Filings

More Tools for ANIK

ANIK Full Stock Analysis ANIK Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper ANIK analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the ANIK stock analysis page.

ANIK Full Analysis

Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.

Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer